Patents by Inventor Alicia Quillevere

Alicia Quillevere has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydrazone derivatives for preventing or treating EBV-related cancers
    Patent number: 11406631
    Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: August 9, 2022
    Assignees: Centre National de la Recherche Scientifique (CNRS)
    Inventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko
  • Novel Hydrazone Derivatives For Preventing Or Treating EBV-Related Cancers
    Publication number: 20210161887
    Abstract: The present invention relates to novel bis-hydrazone derivatives of formula (I): wherein Ar1 and Ar2 may be identical or different and are each independently selected from the group consisting of groups of formula (II) and (III): Y1 and Z1 are independently CH or NRc+, provided that al least one of Y1 and Z1 is NRc+ and at least one of Y1 and Z1 is CH, and Ra, Rb, Rc, X2? and L as defined in the claims, or a hydrate or a solvate thereof. Compositions and kits comprising same are also described. Said bis-hydrazone derivatives of formula (I), compositions and kits are useful as drugs, in particular for treating or preventing cancers associated with the Epstein-Barr Virus.
    Type: Application
    Filed: April 3, 2019
    Publication date: June 3, 2021
    Applicants: Universite de Bretagne Occidentale, Centre Hospitalier Regional Universitaire de Brest, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Institut Curie, Université de Paris, Univ Paris XIII Paris-Nord Villetaneuse, Universite Paris-Saclay
    Inventors: Marc Blondel, Alicia Quillevere, Cécile Voisset, Maria José Lista, Robin Fahraeus, Chrysoula Daskalogianni, Rodrigo Prado-Martins, Marie-Paule Teulade-Fichou, Anton Granzhan, Claire Beauvineau, Oksana Reznichenko